The fight is on in the endpoint security market, and Sophos is the latest vendor to throw punches at next-generation endpoint security startup Cylance. In a blog post Thursday, Kendra Krause, Sophos ...
WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to placebo, improving the ability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback